Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$23.86 -2.8%	$21.61	$13.22 ▼ $62.74	$1.37B	-1.69	933,513 shs	1.24 million shs
MESO Mesoblast	$10.97 +1.1%	$11.46	$5.78 ▼ $22.00	$1.40B	2.5	272,143 shs	301,230 shs
MREO Mereo BioPharma Group	$2.18 -2.7%	$2.27	$1.58 ▼ $5.02	$346.62M	0.53	1.12 million shs	778,260 shs
TVTX Travere Therapeutics	$15.34 -3.2%	$17.72	$6.30 ▼ $25.29	$1.36B	0.88	1.58 million shs	1.77 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	0.00%	-1.80%	+3.41%	+16.41%	-33.76%
MESO Mesoblast	0.00%	-6.06%	-8.21%	-32.40%	+32.80%
MREO Mereo BioPharma Group	0.00%	-2.18%	-10.40%	-11.11%	-24.07%
TVTX Travere Therapeutics	0.00%	-6.88%	-13.58%	-23.29%	+157.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GPCR Structure Therapeutics	2.1978 of 5 stars	3.5	1.0	3.6	1.7	0.6
MESO Mesoblast	1.6522 of 5 stars	3.5	2.0	1.4	0.8	0.6
MREO Mereo BioPharma Group	2.0309 of 5 stars	3.6	2.0	2.9	1.7	0.0
TVTX Travere Therapeutics	2.9399 of 5 stars	4.4	2.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	3.00	Buy	$79.86	234.69% Upside
MESO Mesoblast	3.00	Buy	$18.00	64.08% Upside
MREO Mereo BioPharma Group	3.25	Buy	$7.71	253.87% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$31.79	107.21% Upside

Current Analyst Ratings Breakdown

Latest MREO, GPCR, TVTX, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/14/2025	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00
4/11/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
MESO Mesoblast	$5.67M	247.22	N/A	N/A	$4.21 per share	2.61
MREO Mereo BioPharma Group	$1M	346.62	N/A	N/A	$0.36 per share	6.06
TVTX Travere Therapeutics	$273.53M	4.98	N/A	N/A	$2.67 per share	5.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$89.62M	-$0.87	N/A	N/A	N/A	N/A	-16.37%	-15.68%	8/14/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
MREO Mereo BioPharma Group	-$29.47M	-$0.07	N/A	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
TVTX Travere Therapeutics	-$111.40M	-$2.81	N/A	N/A	N/A	-137.90%	-1,636.87%	-55.95%	8/7/2025 (Estimated)

Latest MREO, GPCR, TVTX, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A
2/27/2025	Q4 2024	GPCR Structure Therapeutics	-$0.23	-$0.22	+$0.01	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	27.63	27.63
MESO Mesoblast	0.21	1.18	1.18
MREO Mereo BioPharma Group	N/A	6.10	6.10
TVTX Travere Therapeutics	24.96	1.71	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
MESO Mesoblast	1.43%
MREO Mereo BioPharma Group	62.83%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	9.43%
MESO Mesoblast	18.80%
MREO Mereo BioPharma Group	5.50%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
MESO Mesoblast	80	127.78 million	103.17 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	148.74 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	75.12 million	Optionable

MREO, GPCR, TVTX, and MESO Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

May 27 at 11:50 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

May 27 at 10:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

May 26 at 10:00 AM | accessnewswire.com

Two Sigma Investments LP Purchases 332,933 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 26 at 4:25 AM | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Raised by Man Group plc

May 26 at 3:58 AM | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Bought by Millennium Management LLC

May 26 at 3:53 AM | marketbeat.com

Ameriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 26 at 3:12 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

May 25 at 10:00 AM | accessnewswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lifted by Voloridge Investment Management LLC

May 25 at 4:55 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

May 24 at 9:00 AM | accessnewswire.com

Two Sigma Advisers LP Grows Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 24 at 4:53 AM | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Nuveen Asset Management LLC

May 24 at 4:05 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

May 23, 2025 | accessnewswire.com

Woodline Partners LP Has $36.83 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 23, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

May 22, 2025 | accessnewswire.com

Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review

May 21, 2025 | investing.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

May 21, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

May 21, 2025 | accessnewswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Rafferty Asset Management LLC

May 21, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

May 20, 2025 | prnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect

May 20, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO, GPCR, TVTX, and MESO Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$23.86 -0.69 (-2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$23.32 -0.54 (-2.28%)

As of 07:18 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Mesoblast NASDAQ:MESO

$10.97 +0.12 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$11.00 +0.03 (+0.27%)

As of 07:55 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mereo BioPharma Group NASDAQ:MREO

$2.18 -0.06 (-2.68%)

Closing price 04:00 PM Eastern

Extended Trading

$2.24 +0.06 (+2.94%)

As of 07:56 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Travere Therapeutics NASDAQ:TVTX

$15.34 -0.50 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$15.45 +0.11 (+0.72%)

As of 05:26 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time